Prescribe ENABLEX for the Control of
Your Overactive Bladder (OAB) Patients
Patients Get Drier Fast
- ENABLEX reduced wetting accidents by up to 52% at 2 weeks1*
Works Across Patient Types†
- Proven to reduce wetting accidents, even in severely incontinent patients2
Patients Stay Dry Long-Term
- Up to 76% reduction in wetting accidents at 3 months3‡
- Confidence that comes with the only published 2-year OAB study4

Results from a multicenter, open-label, 2-year extension study that enrolled 716 patients from two 12-week double-blind feeder studies (n=600 at 3 months, n=543 at 6 months, n=497 at 12 months, and n=466 at 24 months). Total number of older patients (≥65 years): 199 at baseline, 173 at 3 months, 156 at 6 months, 140 at 12 months, and 135 at 24 months.
References:
1. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004;45:420-429.
2. Data on file (NDA, severity data, Hill, business data). Novartis Pharmaceuticals Corporation.
3. Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol. 2005;48:471-477.
4. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int. 2006;98(5):1025-1032.

